Q32 Bio Inc. (QTTB)
NASDAQ: QTTB · Real-Time Price · USD
2.810
+0.050 (1.81%)
At close: Oct 31, 2025, 4:00 PM EDT
2.850
+0.040 (1.42%)
After-hours: Oct 31, 2025, 7:21 PM EDT
Q32 Bio Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
43
Market Cap
34.28M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | -6.65M | -13.30M | -200.00% |
| Dec 31, 2022 | 6.65M | - | - |
| Dec 31, 2021 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionQTTB News
- 11 days ago - Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata - PRNewsWire
- 2 months ago - Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference - PRNewsWire
- 3 months ago - Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 4 months ago - Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer - PRNewsWire
- 6 months ago - Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 6 months ago - Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata - PRNewsWire
- 7 months ago - Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata - PRNewsWire
- 8 months ago - Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire